* Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcu...
* The U.S. FDA approved STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as interchangea...
* YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pedi...
* EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular...
* The AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation was approved in January 2025 by the...
* Approval of AVTOZMA® (tocilizumab-anoh) intravenous infusion expands label to include treatment...
* STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indicatio...
* Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing...
* YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of H...
We are advised by Celltrion that journalists and other readers should disregard the news release, C...
* Six abstracts accepted for presentation includes post hoc analyses and real-world evidence for ...
* STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was lau...
* STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. * Appr...
* OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by theFDA * R...
* STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indicatio...
* Celltrion unveils strategic roadmap for the first time outlining its innovative drug developmen...
* STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO)...
* 78-Week results from Phase III randomized controlled trial (RCT) including switching data from ...
* Celltrion USA has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-appro...
* Pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) previously demonstrated superior efficacy o...